MCID: BNG030
MIFTS: 44

Benign Ependymoma

Categories: Cancer diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Benign Ependymoma

MalaCards integrated aliases for Benign Ependymoma:

Name: Benign Ependymoma 11 14
Ependymoma 43 71
Who Grade Ii Ependymal Tumor 11
Myxopapillary Ependymoma 71
Epithelial Ependymoma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:4844
MeSH 43 D004806
NCIt 49 C3017
SNOMED-CT 68 443643007
UMLS 71 C0014474 C0205769

Summaries for Benign Ependymoma

MalaCards based summary: Benign Ependymoma, also known as ependymoma, is related to spinal cord ependymoma and childhood supratentorial ependymoma, and has symptoms including back pain An important gene associated with Benign Ependymoma is TSC2 (TSC Complex Subunit 2), and among its related pathways/superpathways are Signal Transduction and Disease. The drugs Carboplatin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Benign Ependymoma

Diseases in the Benign Ependymoma family:

Malignant Adult Ependymoma

Diseases related to Benign Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 602)
# Related Disease Score Top Affiliating Genes
1 spinal cord ependymoma 32.5 ZFTA RELA NF2 KIAA1549
2 childhood supratentorial ependymoma 32.5 ZFTA RELA
3 papillary ependymoma 32.3 SYP NF2 GFAP
4 rela fusion-positive ependymoma 32.1 ZFTA RELA OLIG2 KIAA1549 IDH1
5 supratentorial ependymoma 32.0 ZFTA RELA NF2 KIAA1549 IDH1
6 high grade ependymoma 31.9 ZFTA RELA OLIG2 NF2 KIAA1549 IDH1
7 posterior fossa ependymoma 31.9 ZFTA RELA
8 tanycytic ependymoma 31.9 ZFTA RELA OLIG2 NF2 GFAP
9 anaplastic ependymoma 31.8 ZFTA SYP RELA PTEN OLIG2 NF2
10 clear cell ependymoma 31.8 ZFTA SYP RELA OLIG2 NF2 GFAP
11 hydrocephalus 31.0 SYP PTEN MTOR GFAP
12 neurilemmoma 30.8 SYP NF2 NF1 GFAP
13 rhabdoid meningioma 30.5 SYP NF2 GFAP
14 tuberous sclerosis 1 30.5 TSC2 TSC1
15 chordoma 30.3 PTEN MTOR IDH1 GFAP
16 choroid plexus cancer 30.3 ZFTA SYP OLIG2 GFAP
17 brain cancer 30.2 TSC1 SYP PTEN OLIG2 NF2 NF1
18 medulloepithelioma 30.1 SYP OLIG2 GFAP
19 oligodendroglioma 30.1 SYP PTEN OLIG2 NF1 IDH1 GFAP
20 spinal meningioma 30.1 NF2 NF1
21 central neurocytoma 30.1 SYP OLIG2 KIAA1549 IDH1 GFAP
22 medulloblastoma 30.1 TSC2 SYP PTEN OLIG2 NF1 MTOR
23 cerebellar astrocytoma 30.0 NF1 KIAA1549 IDH1
24 gliofibroma 30.0 KIAA1549 GFAP
25 pineal gland cancer 30.0 SYP OLIG2 GFAP
26 meningioma, familial 30.0 TSC1 SYP PTEN OLIG2 NF2 NF1
27 pineocytoma 30.0 SYP GFAP
28 cauda equina syndrome 29.9 SYP GFAP
29 spinal cancer 29.9 ZFTA OLIG2 NF2 NF1 KIAA1549 IDH1
30 chordoid meningioma 29.9 SYP NF2
31 diffuse midline glioma, h3 k27m-mutant 29.9 OLIG2 NF1 KIAA1549 IDH1
32 ganglioneuroma 29.9 TSC1 SYP PTEN GFAP
33 pleomorphic xanthoastrocytoma 29.9 ZFTA SYP NF1 KIAA1549 IDH1
34 neuroendocrine tumor 29.9 SYP RPS6KB1 NF1 MTOR
35 clear cell meningioma 29.9 SYP NF2 GFAP
36 neuroma 29.9 NF2 NF1 GFAP
37 ganglioglioma 29.9 TSC2 TSC1 SYP NF1 GFAP
38 obstructive hydrocephalus 29.9 TSC2 TSC1 SYP OLIG2 NF2 NF1
39 cellular ependymoma 29.8 ZFTA SYP RELA NF2 GFAP
40 neurofibroma 29.8 SYP PTEN NF2 NF1
41 supratentorial primitive neuroectodermal tumor 29.8 SYP IDH1 GFAP
42 pilocytic astrocytoma 29.8 TSC1 SYP PTEN OLIG2 NF1 KIAA1549
43 muscle hypertrophy 29.8 RPS6KB1 MTOR EIF4EBP1
44 myxopapillary ependymoma 29.7 ZFTA SYP RELA NF2 KIAA1549 GFAP
45 von hippel-lindau syndrome 29.7 TSC2 SYP NF1
46 meningothelial meningioma 29.7 NF2 GFAP
47 gemistocytic astrocytoma 29.7 PTEN IDH1 GFAP
48 fibrillary astrocytoma 29.7 NF1 KIAA1549 IDH1 GFAP
49 spinal cord astrocytoma 29.7 NF2 NF1 KIAA1549 IDH1
50 bap1 tumor predisposition syndrome 29.6 TSC2 TSC1 PTEN NF1

Graphical network of the top 20 diseases related to Benign Ependymoma:



Diseases related to Benign Ependymoma

Symptoms & Phenotypes for Benign Ependymoma

UMLS symptoms related to Benign Ependymoma:


back pain

GenomeRNAi Phenotypes related to Benign Ependymoma according to GeneCards Suite gene sharing:

25 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.93 MTOR
2 Decreased viability GR00055-A-2 9.93 MTOR
3 Decreased viability GR00221-A-1 9.93 MLST8 MTOR NF1 RHEB RPS6KB1
4 Decreased viability GR00221-A-2 9.93 NF1
5 Decreased viability GR00221-A-4 9.93 MLST8 MTOR NF1
6 Decreased viability GR00249-S 9.93 NF1
7 Decreased viability GR00301-A 9.93 RPS6KB1
8 Decreased viability GR00342-S-1 9.93 MTOR
9 Decreased viability GR00342-S-2 9.93 MTOR
10 Decreased viability GR00381-A-1 9.93 RPS6KB1
11 Decreased viability GR00386-A-1 9.93 NF1 RHEB
12 Decreased viability GR00402-S-2 9.93 RPS6KB1
13 Decreased viability with paclitaxel GR00179-A-1 9.02 MTOR RPS6KB1
14 Decreased viability with paclitaxel GR00179-A-2 9.02 MTOR
15 Decreased viability with paclitaxel GR00179-A-3 9.02 MTOR RPS6KB1

MGI Mouse Phenotypes related to Benign Ependymoma:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.4 FKBP1A GFAP IDH1 MLST8 MTOR NF1
2 homeostasis/metabolism MP:0005376 10.36 EIF4EBP1 FKBP1A GFAP IDH1 KIAA1549 MTOR
3 growth/size/body region MP:0005378 10.36 EIF4EBP1 FKBP1A GFAP IDH1 MLST8 MTOR
4 muscle MP:0005369 10.32 EIF4EBP1 FKBP1A GFAP MTOR NF1 OLIG2
5 normal MP:0002873 10.24 FKBP1A GFAP MTOR NF1 PTEN RELA
6 embryo MP:0005380 10.15 FKBP1A MLST8 MTOR NF1 NF2 PTEN
7 cellular MP:0005384 10.13 EIF4EBP1 FKBP1A GFAP MTOR NF1 OLIG2
8 liver/biliary system MP:0005370 10.1 FKBP1A NF1 NF2 PTEN RELA RPTOR
9 endocrine/exocrine gland MP:0005379 10.1 MTOR NF1 NF2 PTEN RELA RHEB
10 neoplasm MP:0002006 10.09 NF1 NF2 OLIG2 PTEN RPS6KB1 TSC1
11 cardiovascular system MP:0005385 10.07 EIF4EBP1 FKBP1A GFAP MLST8 MTOR NF1
12 adipose tissue MP:0005375 10.02 EIF4EBP1 KIAA1549 MTOR OLIG2 PTEN RPS6KB1
13 behavior/neurological MP:0005386 9.97 FKBP1A GFAP KIAA1549 MTOR NF1 NF2
14 respiratory system MP:0005388 9.61 FKBP1A IDH1 MTOR NF1 NF2 OLIG2
15 mortality/aging MP:0010768 9.53 EIF4EBP1 FKBP1A GFAP IDH1 MLST8 MTOR

Drugs & Therapeutics for Benign Ependymoma

Drugs for Benign Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904
2
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
3
Temozolomide Approved, Investigational Phase 2, Phase 3 85622-93-1 5394
4
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
5
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
6
Valproic acid Approved, Investigational Phase 2, Phase 3 99-66-1 3121
7
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
8
Picropodophyllin Approved, Investigational Phase 3 518-28-5, 477-47-4 10607 72435
9
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
10
Trofosfamide Investigational Phase 2, Phase 3 22089-22-1 65702
11 Immunosuppressive Agents Phase 2, Phase 3
12 Immunologic Factors Phase 2, Phase 3
13 Antineoplastic Agents, Alkylating Phase 2, Phase 3
14 Antirheumatic Agents Phase 2, Phase 3
15 Alkylating Agents Phase 2, Phase 3
16
Etoposide phosphate Phase 2, Phase 3 16760419
17 Anticonvulsants Phase 2, Phase 3
18 Psychotropic Drugs Phase 2, Phase 3
19 Tubulin Modulators Phase 3
20 Antimitotic Agents Phase 3
21 Keratolytic Agents Phase 3
22
Lenograstim Approved, Investigational Phase 2 135968-09-1
23
Coenzyme M Approved, Investigational Phase 2 3375-50-6 598 23662354
24
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
25
Sargramostim Approved, Investigational Phase 2 123774-72-1
26
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
27
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
29
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
30
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
31
Ivosidenib Approved, Investigational Phase 2 1448347-49-6 78140854 71657455
32
Acetaminophen Approved Phase 2 103-90-2 1983
33
Promethazine Approved, Investigational Phase 2 60-87-7 4927
34
Carbamide peroxide Approved Phase 2 124-43-6
35
Iodine Approved, Investigational Phase 2 7553-56-2 807
36
Histamine Approved, Investigational Phase 2 51-45-6 774
37
Ondansetron Approved Phase 2 99614-02-5 4595
38
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
39
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
40
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 596 6253 6175
41
Fenofibric acid Approved Phase 2 42017-89-0 64929
42
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
43
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
44
Nivolumab Approved Phase 2 946414-94-4
45
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
46
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
47
Memantine Approved, Investigational Phase 2 41100-52-1, 19982-08-2 4054
48
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286
49
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
50
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837

Interventional clinical trials:

(show top 50) (show all 148)
# Name Status NCT ID Phase Drugs
1 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
2 Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents Completed NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;intraventricular etoposide;trofosfamide, etoposide
3 An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3 16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
4 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years Active, not recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine
5 Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
6 Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
7 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
8 A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma Completed NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
9 A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients Completed NCT01462695 Phase 2 Sunitinib Malate
10 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
11 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
12 Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial Completed NCT01295944 Phase 2 Carboplatin;Bevacizumab
13 A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma Completed NCT00826241 Phase 2 Temozolomide;Lapatinib
14 Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
15 A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
16 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
17 SIOP Study of Combined Modality Treatment in Childhood Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
18 A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed NCT00883688 Phase 2 Bevacizumab;Lapatinib
19 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
20 Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020) Completed NCT04730349 Phase 1, Phase 2
21 A Phase II Study of Pemetrexed in Children With Recurrent Malignancies Completed NCT00520936 Phase 2 pemetrexed
22 Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
23 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
24 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
25 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
26 A PHASE II TRIAL OF ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF RECURRENT EPENDYMOMAS Completed NCT00002876 Phase 2 cisplatin;etoposide
27 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations Recruiting NCT04284774 Phase 2 Tipifarnib
28 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations Recruiting NCT04320888 Phase 2 Selpercatinib
29 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations Recruiting NCT04195555 Phase 2 Ivosidenib
30 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations Recruiting NCT03213652 Phase 2 Ensartinib
31 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib Sulfate
32 Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and Ependymoma Recruiting NCT04743661 Phase 2 Irinotecan;Temozolomide;Bevacizumab;Omburtamab I-131;Liothyronine;SSKI;Dexamethasone;Antipyretic;Antihistamine;anti-emetics
33 A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma and ATRT Recruiting NCT01356290 Phase 2 Bevacizumab;Thalidomide;Celecoxib;Fenofibric acid;Etoposide;Cyclophosphamide;Etoposide phosphate;Cytarabine
34 Methionine PET/CT Studies In Patients With Cancer Recruiting NCT00840047 Phase 2 Methionine
35 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib;Neratinib
36 Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG Recruiting NCT04049669 Phase 2 Indoximod;Temozolomide;Cyclophosphamide;Etoposide;Lomustine
37 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
38 NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors Recruiting NCT03213678 Phase 2 Samotolisib
39 Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study Recruiting NCT03194906 Phase 2 Memantine
40 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib Sulfate;Olaparib;Palbociclib;Samotolisib;Selpercatinib;Selumetinib Sulfate;Tazemetostat;Tipifarnib;Ulixertinib;Vemurafenib
41 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
42 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes Active, not recruiting NCT03526250 Phase 2 Palbociclib
43 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes Active, not recruiting NCT03233204 Phase 2 Olaparib
44 A Phase II Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma Active, not recruiting NCT02125786 Phase 2 ^1^8F-Fluorodeoxyglucose;^1^1C-methionine
45 Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Active, not recruiting NCT00602667 Phase 2 Induction Chemotherapy;Low-Risk Therapy;High-Risk Therapy;Intermediate-Risk Therapy
46 Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma Active, not recruiting NCT02155920 Phase 2 Everolimus
47 A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation: An Assessment of Long Term Neurocognitive, Neuroendocrine Adn Ototoxicity Outcomes Active, not recruiting NCT01288235 Phase 2
48 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations Active, not recruiting NCT03698994 Phase 2 Ulixertinib
49 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex Active, not recruiting NCT03213665 Phase 2 Tazemetostat
50 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations Active, not recruiting NCT03220035 Phase 2 Vemurafenib

Search NIH Clinical Center for Benign Ependymoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine

Cochrane evidence based reviews: ependymoma

Genetic Tests for Benign Ependymoma

Anatomical Context for Benign Ependymoma

Organs/tissues related to Benign Ependymoma:

MalaCards : Brain, Spinal Cord, T Cells, Nk Cells, Endothelial, Liver

Publications for Benign Ependymoma

Articles related to Benign Ependymoma:

(show all 17)
# Title Authors PMID Year
1
Health-Related Quality of Life After Microscopic Total Removal of Spinal Intramedullary Ependymomas in a Single-Institute 3-Year Prospective Study. 62
32001405 2020
2
Benign ependymoma with extensive intracranial and spinal cerebrospinal fluid dissemination: case report and literature review. 62
28633540 2019
3
[Brachioradial pruritus revealing an ependymoma]. 62
19442801 2009
4
Childhood ependymoma: a systematic review of treatment options and strategies. 62
12895136 2003
5
Late dissemination of fourth ventricle ependymoma: a case report. 62
11817702 2001
6
Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas. 62
11908872 2001
7
Primary intradural extramedullary ependymoma: case report and review of the literature. 62
10908946 2000
8
The importance of surgery in supratentorial ependymomas. Long-term survival in a series of 23 cases. 62
10804053 2000
9
Ependymoma of the spinal cord and the cauda equina region. 62
10229532 1999
10
[Rapidly enlarging supratentorial ependymoma in a child presenting initially with a small calcified lesion: case report]. 62
9266564 1997
11
Interstitial irradiation of a large, low grade ependymoma with stereotactically implanted iodine-125 seeds. Case report. 62
8333303 1993
12
Recurrent intracranial ependymomas in children. Survival, patterns of failure, and prognostic factors. 62
2364367 1990
13
Intramedullary ependymoma of the spinal cord. 62
2319309 1990
14
Localization and significance of peanut agglutinin-binding sites on ependymoma cells. 62
2360409 1990
15
[Results of combined radiochemotherapy of intracranial ependymoma]. 62
3114661 1987
16
Initial experience with MR-imaging of intracranial midline-lesions and lesions of the cervical spine at half Tesla. 62
6099524 1984
17
An epithelial ependymoma in an ostrich. 62
13286177 1956

Variations for Benign Ependymoma

Expression for Benign Ependymoma

Search GEO for disease gene expression data for Benign Ependymoma.

Pathways for Benign Ependymoma

Pathways related to Benign Ependymoma according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1 13.85 EIF4EBP1 FKBP1A GFAP MLST8 MTOR NF1
2
Show member pathways
13.8 FKBP1A IDH1 KIAA1549 MLST8 MTOR NF1
3
Show member pathways
13.53 TSC2 TSC1 RPS6KB1 RELA PTEN NF2
4
Show member pathways
13.37 TSC2 PTEN NF1 MTOR MLST8 KIAA1549
5
Show member pathways
13.18 TSC2 TSC1 RPTOR RPS6KB1 RHEB MTOR
6
Show member pathways
13.08 EIF4EBP1 MLST8 MTOR PTEN RELA RHEB
7
Show member pathways
13.07 TSC2 RPTOR RHEB PTEN MTOR MLST8
8
Show member pathways
13.03 MLST8 MTOR PTEN RHEB RPTOR TSC1
9
Show member pathways
12.93 TSC2 RPS6KB1 RHEB RELA PTEN MTOR
10
Show member pathways
12.88 TSC2 TSC1 RPTOR RPS6KB1 RHEB PTEN
11
Show member pathways
12.85 TSC2 TSC1 RPTOR RHEB MTOR MLST8
12
Show member pathways
12.83 MTOR NF1 PTEN RELA RHEB RPS6KB1
13 12.74 EIF4EBP1 MLST8 MTOR NF2 PTEN RHEB
14
Show member pathways
12.67 EIF4EBP1 MLST8 MTOR PTEN RHEB RPS6KB1
15 12.51 TSC2 RPTOR PTEN IDH1
16
Show member pathways
12.44 TSC2 TSC1 RPTOR RPS6KB1 MTOR MLST8
17
Show member pathways
12.42 TSC2 TSC1 RPS6KB1 RHEB RELA PTEN
18
Show member pathways
12.35 EIF4EBP1 MTOR RPS6KB1 RPTOR TSC1 TSC2
19
Show member pathways
12.33 EIF4EBP1 MLST8 MTOR PTEN RHEB RPS6KB1
20
Show member pathways
12.32 RPS6KB1 RELA PTEN MTOR
21 12.3 TSC2 TSC1 RHEB PTEN NF1 MTOR
22
Show member pathways
12.29 TSC2 TSC1 RPTOR RPS6KB1 RHEB MTOR
23
Show member pathways
12.28 TSC2 RPS6KB1 RHEB MTOR
24
Show member pathways
12.27 EIF4EBP1 MTOR PTEN RELA RPS6KB1 TSC2
25
Show member pathways
12.24 TSC2 TSC1 RPTOR RHEB RELA PTEN
26 12.22 SYP RPTOR RPS6KB1 RELA PTEN MTOR
27
Show member pathways
12.2 MLST8 MTOR RHEB RPTOR TSC1 TSC2
28
Show member pathways
12.16 TSC2 RPS6KB1 RHEB MTOR EIF4EBP1
29
Show member pathways
12.16 TSC2 TSC1 RPTOR RPS6KB1 RHEB MTOR
30
Show member pathways
12.11 MLST8 MTOR NF1 PTEN RHEB RPS6KB1
31
Show member pathways
12.1 EIF4EBP1 FKBP1A MLST8 MTOR RHEB RPS6KB1
32 12.1 EIF4EBP1 MLST8 MTOR PTEN RHEB RPS6KB1
33 12.03 TSC2 RPTOR PTEN MTOR MLST8
34 12.02 TSC2 TSC1 TBC1D7 RHEB PTEN
35 12.01 TSC2 TSC1 RPTOR RHEB PTEN MTOR
36 11.98 TSC2 TSC1 RPTOR RHEB PTEN MTOR
37 11.95 RPS6KB1 RELA EIF4EBP1
38 11.94 TSC2 TSC1 RPTOR RPS6KB1 RHEB MTOR
39 11.92 PTEN MTOR MLST8
40 11.88 RPS6KB1 RELA MTOR
41 11.88 RELA PTEN MTOR
42 11.85 RPS6KB1 MTOR EIF4EBP1
43 11.83 RPTOR MTOR MLST8 EIF4EBP1
44 11.83 TSC2 TSC1 RPTOR MTOR MLST8
45 11.79 SYP OLIG2 GFAP
46
Show member pathways
11.78 TSC2 MTOR MLST8
47 11.74 MTOR NF1 PTEN
48
Show member pathways
11.59 EIF4EBP1 MTOR NF1 PTEN RHEB RPS6KB1
49 11.58 TSC2 TSC1 RPTOR MTOR MLST8
50 11.57 RPS6KB1 RELA PTEN

GO Terms for Benign Ependymoma

Cellular components related to Benign Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 TORC1 complex GO:0031931 9.43 RPTOR MTOR MLST8
2 TSC1-TSC2 complex GO:0033596 9.1 TSC2 TSC1 TBC1D7

Biological processes related to Benign Ependymoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell cycle GO:0051726 10.2 NF2 PTEN RHEB TSC1 TSC2
2 cellular response to hypoxia GO:0071456 10.14 RPTOR PTEN MTOR MLST8
3 negative regulation of autophagy GO:0010507 10.06 RPTOR MTOR MLST8
4 positive regulation of stress fiber assembly GO:0051496 10.04 TSC1 NF2 MTOR
5 protein kinase B signaling GO:0043491 10.03 TSC2 RPS6KB1 PTEN
6 positive regulation of TOR signaling GO:0032008 10 RPTOR RHEB MLST8
7 myelination GO:0042552 9.99 TSC1 PTEN OLIG2
8 negative regulation of TOR signaling GO:0032007 9.99 TSC2 TSC1 TBC1D7
9 positive regulation of oligodendrocyte differentiation GO:0048714 9.97 RHEB OLIG2 MTOR
10 positive regulation of glycolytic process GO:0045821 9.95 MLST8 MTOR RPTOR
11 cellular response to nutrient levels GO:0031669 9.93 RPTOR MTOR MLST8
12 positive regulation of lipid biosynthetic process GO:0046889 9.91 RPTOR MTOR MLST8
13 negative regulation of Schwann cell proliferation GO:0010626 9.88 NF2 NF1
14 cellular response to osmotic stress GO:0071470 9.88 RPTOR MTOR MLST8
15 TORC1 signaling GO:0038202 9.85 RPTOR MTOR MLST8
16 negative regulation of cell size GO:0045792 9.8 MTOR PTEN TSC1
17 oligodendrocyte differentiation GO:0048709 9.8 RHEB OLIG2 NF1 MTOR
18 positive regulation of pentose-phosphate shunt GO:1905857 9.63 RPTOR MTOR MLST8
19 Schwann cell proliferation GO:0014010 9.43 NF2 NF1 GFAP
20 TOR signaling GO:0031929 9.32 RPTOR RPS6KB1 MTOR MLST8 EIF4EBP1

Molecular functions related to Benign Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase III type 3 promoter sequence-specific DNA binding GO:0001006 9.56 RPTOR MTOR
2 TFIIIC-class transcription factor complex binding GO:0001156 9.46 RPTOR MTOR
3 RNA polymerase III type 2 promoter sequence-specific DNA binding GO:0001003 9.26 RPTOR MTOR
4 RNA polymerase III type 1 promoter sequence-specific DNA binding GO:0001002 8.92 RPTOR MTOR

Sources for Benign Ependymoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....